Computational Discovery of Potential HDAC6 Inhibitors through Integrated Virtual Screening and Molecular Dynamics Approaches
Pharmaceutical Sciences and Drug Design · 2026 · 6 (2) · 1-18
DOI: 10.51847/n3qdrlsgru ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceutical Sciences and Drug Design, 2026. Verfasst von Maria Gonzalez und 3 weiteren Autor:innen. Die Arbeit nennt 40 Literaturangaben.
Abstract (Originalsprache)
Histone deacetylase 6 has emerged as a significant therapeutic target due to its essential role in neurological, inflammatory, and other pathological conditions. At present, no HDAC6-targeting agents have received FDA approval, and most pipeline candidates exhibit limitations, including insufficient target occupancy, inadequate brain exposure, and poor tolerability. A small number of clinical-stage candidates exist, primarily for non-CNS malignancies. Yet, their pharmacokinetic drawbacks preclud
Zitieren
APA
Gonzalez, M., Ruiz, J., Torres, L., & Ruiz, E. (2026). Computational Discovery of Potential HDAC6 Inhibitors through Integrated Virtual Screening and Molecular Dynamics Approaches. Pharmaceutical Sciences and Drug Design, 6(2), 1-18. https://doi.org/10.51847/n3qdrlsgru
Vancouver
Gonzalez M, Ruiz J, Torres L, Ruiz E. Computational Discovery of Potential HDAC6 Inhibitors through Integrated Virtual Screening and Molecular Dynamics Approaches. Pharmaceutical Sciences and Drug Design. 2026;6(2):1-18. doi:10.51847/n3qdrlsgru
BibTeX
@article{Gonzalez2026,
author = {Gonzalez, Maria and Ruiz, Javier and Torres, Lucia and Ruiz, Elena},
title = {Computational Discovery of Potential HDAC6 Inhibitors through Integrated Virtual Screening and Molecular Dynamics Approaches},
journal = {Pharmaceutical Sciences and Drug Design},
year = {2026},
volume = {6},
number = {2},
pages = {1--18},
doi = {10.51847/n3qdrlsgru}
}
EUVIMED